|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
|
CA3112322A1
(en)
|
2018-09-29 |
2020-04-02 |
Novartis Ag |
Manufacture of compounds and compositions for inhibiting the activity of shp2
|
|
CN111647000B
(zh)
*
|
2019-03-04 |
2021-10-12 |
勤浩医药（苏州）有限公司 |
吡嗪类衍生物及其在抑制shp2中的应用
|
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
EP4169913A4
(en)
*
|
2020-06-22 |
2024-10-30 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
|
|
CN115916786B
(zh)
|
2020-07-08 |
2025-10-17 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物的制造
|
|
WO2022006780A1
(en)
*
|
2020-07-08 |
2022-01-13 |
Novartis Ag |
Manufacture of compounds and compositions for inhibiting activity of shp2
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
MX2023003060A
(es)
|
2020-09-15 |
2023-04-05 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
|
|
CN116348466B
(zh)
*
|
2020-09-23 |
2025-05-30 |
上海齐鲁制药研究中心有限公司 |
吡嗪硫联苯基类化合物及其应用
|
|
MX2023012929A
(es)
*
|
2021-05-05 |
2023-11-13 |
Huyabio Int Llc |
Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.
|
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
IL308234A
(en)
|
2021-05-05 |
2024-01-01 |
Huyabio Int Llc |
Monotherapy with an SHP2 inhibitor and its uses
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
|
CA3217084A1
(en)
*
|
2021-05-05 |
2022-11-10 |
Farbod Shojaei |
Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
|
|
CN115340561A
(zh)
*
|
2021-05-14 |
2022-11-15 |
药雅科技(上海)有限公司 |
Shp2磷酸酶稠环类抑制剂的制备及其应用
|
|
TW202244049A
(zh)
*
|
2021-05-12 |
2022-11-16 |
大陸商藥雅科技（上海）有限公司 |
Shp2磷酸酶抑制劑的製備及其應用
|
|
CN115340559A
(zh)
*
|
2021-05-12 |
2022-11-15 |
药雅科技(上海)有限公司 |
Shp2磷酸酶杂环类抑制剂的制备及其应用
|
|
CN114716448B
(zh)
*
|
2021-05-13 |
2024-01-30 |
中国科学院上海药物研究所 |
抑制shp2活性的杂环化合物、其制备方法及用途
|
|
WO2022259157A1
(en)
|
2021-06-09 |
2022-12-15 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
CN115594666B
(zh)
*
|
2021-07-07 |
2024-05-31 |
海创药业股份有限公司 |
一种磷酸酶降解剂的合成和应用
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
JP2024534127A
(ja)
|
2021-08-25 |
2024-09-18 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|
|
CA3224341A1
(en)
|
2021-09-01 |
2023-03-09 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
CN116063307B
(zh)
*
|
2021-10-29 |
2025-08-19 |
中国药科大学 |
Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用
|
|
WO2023122938A1
(en)
*
|
2021-12-28 |
2023-07-06 |
Js Innomed Holdings Ltd. |
Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
CN116947867B
(zh)
*
|
2022-04-18 |
2025-12-30 |
上海茂晟康慧科技有限公司 |
一种嘧啶-4(3h)-酮类杂环化合物的重要中间体的制备方法
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN115521305B
(zh)
*
|
2022-09-20 |
2024-11-08 |
中国药科大学 |
Shp2&nampt双靶向化合物及其药物组合物和用途
|
|
WO2024081674A1
(en)
|
2022-10-11 |
2024-04-18 |
Aadi Bioscience, Inc. |
Combination therapies for the treatment of cancer
|
|
CN115677661B
(zh)
*
|
2022-10-27 |
2024-04-19 |
中国药科大学 |
杂环硫醚类化合物及其用途和药物组合物
|
|
WO2024125603A1
(zh)
*
|
2022-12-15 |
2024-06-20 |
江苏威凯尔医药科技有限公司 |
Shp2抑制剂及其应用
|
|
CN120826403A
(zh)
*
|
2023-02-24 |
2025-10-21 |
深圳真实生物医药科技有限公司 |
Shp2抑制剂化合物及其应用
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
CN121263418A
(zh)
|
2023-04-07 |
2026-01-02 |
锐新医药公司 |
大环ras抑制剂
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
CN121568944A
(zh)
*
|
2023-07-11 |
2026-02-24 |
勤浩医药(苏州)股份有限公司 |
用作shp2抑制剂的杂环化合物、包含其的药物组合物及其制备方法和用途
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
TW202529768A
(zh)
|
2023-09-29 |
2025-08-01 |
大陸商德昇濟醫藥（無錫）有限公司 |
癌症治療的療法
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN118108707A
(zh)
*
|
2024-02-04 |
2024-05-31 |
中国药科大学 |
吡嗪类化合物及其制备方法、药物组合物和应用
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025242126A1
(zh)
*
|
2024-05-22 |
2025-11-27 |
上海正大天晴医药科技开发有限公司 |
一种药物组合及其应用
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|